Schlosser

Germany
|
2022
  • Immunocompromised host
  • Fragile population
  • SARS-CoV-2
  • Post-COVID-19

MonVIP

France
|
2023
  • Adults
  • People at high risk of STIs
  • People living with HIV
  • Immunocompromised host
  • Fragile population
  • PrEP users
  • Hospital wide
  • Outpatient clinic
  • Infectious diseases unit
  • Monkeypox virus
  • Monkeypox virus infection

NOVELLA

Russian Federation
|
2023-2024
  • Adults
  • Elderly
  • Immunocompromised host
  • Fragile population
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • AZD3152
  • Monoclonal antibodies

PISCIS

Spain
|
2022-2022
  • Adults
  • People at high risk of STIs
  • People living with HIV
  • Immunocompromised host
  • Fragile population
  • PrEP users
  • Non-hospital health centre
  • Telemedicine
  • Monkeypox virus
  • Monkeypox virus infection
  • Vaccination
  • Pharmacological intervention

MASH-1

United Kingdom France Spain Poland
|
2024-2024
  • Adults
  • Elderly
  • People at high risk of STIs
  • People living with HIV
  • Immunocompromised host
  • Fragile population
  • PrEP users
  • Outpatient clinic
  • Non-hospital health centre
  • STD/STI clinic
  • Monkeypox virus
  • Monkeypox virus infection

Gotz

Germany
|
2022-2023
  • Adults
  • Elderly
  • Immunocompromised host
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2

DegliAntoni

Italy
|
2020-2022
  • Adults
  • People living with HIV
  • Immunocompromised host
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19

Destremau

France
|
2020-2023
  • Adults
  • Elderly
  • Immunocompromised host
  • Fragile population
  • Hospital wide
  • Outpatient clinic
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Non pharmacological intervention
  • Convalescent plasma

Drysdale

United Kingdom
|
2021-2022
  • Adults
  • Paediatric
  • Elderly
  • Immunocompromised host
  • Fragile population
  • Outpatient clinic
  • Non-hospital health centre
  • Community
  • SARS-CoV-2
  • Acute SARS-CoV-2
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab